China Mesalazine Market Analysis:
Mesalazine is an aminosalicylate prescription drug for treating mild to moderate active ulcerative colitis, also keep remission when it has been established. Mesalazine is an anti-inflammatory medication that is structurally linked to non-steroidal anti-inflammatory drugs and salicyclates such as acetylsalicylic acid and is used to treat inflammatory bowel illnesses such as Crohn’s disease and ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease of bowel that involves inflammation of the lining of the large intestine (colon). It causes ulcers on the lining of the colon, which can lead to bleeding and the production of mucus and pus. Mesalazine acts by blocking the formation of certain chemical molecules that cause pain and swelling, such as prostaglandins, which aids in the reduction of swelling and redness of the intestines and gives relief from symptoms such as stomach discomfort or bleeding.
The China mesalazine market is predicted to be worth $51.6 million in 2022, with a CAGR of 3.1% the throughout the predicted period (2022-2030).
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/5371
China Mesalazine Market – Drivers
Growing inorganic initiatives, such as product debuts by prominent market competitors, are likely to propel the China mesalazine market forward. Tillotts Pharma AG, for example, released Asacol 800 mg tablets (mesalazine) as the primary therapy for moderate to mild Ulcerative Colitis (UC) in China in July 2021. It will bring a stronger mesalazine tablet formulation to the Chinese market in order to improve the treatment choices for patients suffering from ulcerative colitis in China.
China Mesalazine Market – Impact of Coronavirus (COVID-19) Pandemic
The illness has spread to over 100 nations after the COVID-19 viral epidemic in December 2019, and the World Health Organization designated it a state medical crisis on January 30, 2020.
The COVID-19 has the potential to impact the economy in three ways: directly impacting medication supply and demand, disrupting distribution networks, and having a financial impact on enterprises and financial markets. Several nations, including the United Arab Emirates, Egypt, Saudi Arabia, India, China and others, are having difficulty transporting pharmaceuticals from one location to another due to national lockdowns.
The COVID-19 epidemic, on the other hand, had a favorable influence on the Chinese mesalazine market. For example, harmed people with Inflammatory Bowel Disease (IBD) both physically and psychologically, according to figures released in 2020 month of May by the National Center for Biotechnology Information. Most IBD patients were sick during the beginning and present periods of the epidemic, and they didn’t have to modify their meds.
China Mesalazine Market: Key Developments
Joint partnerships between industry participants are projected to fuel China mesalazine market expansion throughout the forecast period. For example, in November 2022, Alembic Pharmaceutical Limited, a pharmaceutical firm, reported that it had acquired FDA clearance for the Abbreviated New Drug Application (ANDA) for Mesalazine extended-release capsules of strength 0.375 g.
China Mesalazine Market: Restraint
The availability of mesalazine substitutes is projected to impede the growth of the China mesalazine market during the forecast period. The first-line therapy for ulcerative colitis is aminosalicylate (5-ASA). In addition, several pharmacological classes are approved to treat Chron’s disease, inflammatory bowel disease and ulcerative colitis. Biologic/Biosimilar Therapies, Targeted Synthetic Small Molecules (Immunosuppressants), immunomodulators and Corticosterids and Biologic/Biosimilar Therapies are examples of these drugs (Monoclonal Antibodies). Furthermore, the emergence of biosimilars has transformed the treatment of Ulcerative Colitis (UC). It is a biological therapy for IBD, such as Crohn’s disease and ulcerative colitis. These medicines are much less costly than other medications, making it more accessible to Chinese citizens.
China Mesalazine Market – Key Players
Dr. Falk Pharma Gmbh, Viatris Inc., FERRING B.V., Salix Pharmaceuticals, Norvatis AG, Tillotts Pharma AG, GSK Plc., Takeda Pharmaceuticals Company Limited, Hoffmann-La Roche AG, AbbVie Inc, Ltd., Heilongjiang Tianhong Pharmaceutical Co., Shanghai Pharmaceuticals Holding Co Ltd., ALP Pharm Beijing Co., Ltd., Jiangsu Jubang Pharmaceuticals Co., Ltd., and Zhejiang Hengkang Pharmaceuticals Co. Ltd., is a major participant in the Chinese mesalazine business.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/5371
Reasons to buy this China Mesalazine Market Report:
✅️ It attempts an analysis of the competing scenario.
✅️ The current and exceptional product revenue market.
✅️ An in-depth data on the regional investigation and competitive landscape structure.
✅️ It benefits in creating an awareness of the important key product segments.
✅️ The marketing strategies, opportunities, and development factors are explained.
✅️ China Mesalazine market size estimation and recent advancements in the industry are explained.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 China Mesalazine Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: China Mesalazine Industry Impact
Chapter 2 China Mesalazine Competition by Types, Applications, and Top Regions and Countries
2.1 China Mesalazine (Volume and Value) by Type
2.3 China Mesalazine (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 China Mesalazine Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures in China Mesalazine Business
Chapter 6 China Mesalazine Market Forecast (2022-2028)
Chapter 7 Conclusions
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5371
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027